Continuous glucose monitoring may provide a better understanding of the early stages of diabetes progression in youth with cystic fibrosis, according to study results published in Diabetes Care.
According to researchers, continuous glucose monitoring may detect early glucose abnormalities in prediabetes and provide insight into disease pathophysiology; however, there is insufficient data to support the use of continuous glucose monitoring in the diagnosis of diabetes. The objective of this study was to determine whether specific continuous glucose monitoring measures differ among groups of youth at risk for different types of diabetes.
Data from 108 youth patients at risk for diabetes were analyzed. Patients were aged 10 to 18 years and had HbA1c <6.5% (48 mmol/mol). For the analysis, data were combined from 3 groups: antibody-positive children from the Diabetes Autoimmunity Study in the Young (n=24), youth with cystic fibrosis from the Glycemic Monitoring in Cystic Fibrosis Study (n=42), and youth with overweight or obesity (body mass index ≥85th percentile at risk for type 2 diabetes; n=42).
The researchers revealed that the average sensor glucose levels on continuous glucose monitoring did not vary among groups. However, patients with cystic fibrosis and pre-type 1 diabetes had significantly higher measures of glycemic variability including maximum glucose (208 mg/dL and 202 mg/dL, respectively; P =.0001), standard deviation (22 mg/dL and 24 mg/dL, respectively; P =.002), and mean amplitude of glycemic excursions (41 and 45, respectively; P =.006).
Continuous glucose monitoring may eventually become the new standard in the diagnosis of diabetes, as it informs a better understanding of early diabetes progression in youth, according to the researchers.
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Chan CL, Steck AK, Severn C, Pyle L, Rewers M, Zeitler PS. Lessons from continuous glucose monitoring in youth with pre-type 1 diabetes, obesity, and cystic fibrosis [published online January 14, 2020]. Diabetes Care. doi:10.2337/dc19-1690